{
    "clinical_study": {
        "@rank": "148213", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Assess the safety and efficacy of olsalazine, a dimer of 5-aminosalicylic acid, in men\n      with ankylosing spondylitis unresponsive to nonsteroidal anti-inflammatory drugs and\n      physiotherapy."
        }, 
        "brief_title": "Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis", 
        "completion_date": "December 1999", 
        "condition": "Ankylosing Spondylitis", 
        "condition_browse": {
            "mesh_term": [
                "Spondylitis", 
                "Spondylitis, Ankylosing"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: Patients are treated with daily olsalazine.  The dose is increased each\n      week until the protocol dose is reached.\n\n      Supplemental acetaminophen is allowed; nonsteroidal anti-inflammatory drugs continue\n      unchanged.  Concurrent sulfasalazine is prohibited."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Meets modified New York diagnostic criteria\n\n          -  Active disease, i.e., morning stiffness for more than 30 minutes\n\n          -  Failed or experienced nonlife-threatening reaction to prior sulfasalazine\n\n          -  No significant hematologic, hepatic, or renal disease"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "4", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004288", 
            "org_study_id": "199/11716", 
            "secondary_id": "URMC-44"
        }, 
        "intervention": {
            "intervention_name": "olsalazine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Olsalazine"
        }, 
        "keyword": [
            "ankylosing spondylitis", 
            "genetic diseases and dysmorphic syndromes", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of Rochester", 
            "last_name": "Samuel H. Zwillich", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004288"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Rochester", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "May 1996", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2000"
    }, 
    "geocoordinates": {}
}